Compare International Business Machines Corp (IBM) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance

IBM trades at $220.51, down 0.35% with a bearish technical signal. The company reported strong Q1 2026 earnings beat but missed Q2 expectations. Revenue growth accelerated to $67.54B in 2025 with improved net margin of 15.52%. Recent news highlights IBM's AI platform expansion with self-hosted deployment options, while analyst consensus remains positive with a $256.69 price target representing 16% upside potential.

IBM presents a mixed investment case with solid fundamentals offset by technical weakness. The company's pivot to hybrid cloud and AI consulting shows promise with $5.5B in generative AI bookings, but faces execution risks amid cyclical mainframe weakness. Current valuation at 20.13 P/E appears reasonable given the 34.62% ROE, though near-term price pressure may persist until Q3 earnings clarity emerges.

DENTSPLY SIRONA (XRAY) trades at $8.54, near its 52-week low, with bearish technical indicators and mixed fundamentals. The company reported Q2 2026 EPS of $0.52 beating expectations but revenue declined 4.1% year-over-year. Net income remains negative at -$598 million for 2025, though margins show slight improvement. Analyst consensus is mixed with 37.5% buy ratings but a $13.40 price target suggesting 57% upside potential from current levels.

The stock presents a high-risk turnaround opportunity with significant upside if management's restructuring efforts succeed, but faces headwinds from declining sales, margin pressure, and competitive challenges in dental markets. Institutional ownership changes and ongoing transformation investments create both uncertainty and potential for recovery.